|
Corporate Profile
Lexicon Pharmaceuticals is a biopharmaceutical company focused on drug discovery. Our company is dedicated to discovering and developing breakthrough treatment for human disease based on understanding how genes work to maintain health.
We are using our proprietary gene knockout technology on an unprecedented scale to systematically discover the physiological and behavioral functions of 5,000 genes. Through this initiative, known as the Genome5000™ program, we have identified and validated more than 100 drug targets and created a unique, growing clinical pipeline.
All of our drug targets have been identified internally as part of our Genome5000 program. Currently, we are working towards commercialization of our discoveries in order to fight human diseases in cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology.
Investor Highlights
- Four drug candidates in human clinical trials identified through our Genome5000 program
- LX6171 in Phase 2 clinical trials for cognitive disorders
- LX1031 in Phase 1 clinical trials for irritable bowel syndrome
- LX2931 in Phase 1 clinical trials for rheumatoid arthritis
- LX1032 in Phase 1 clinical trials for symptoms associated with carcinoid syndrome (Fast Track status)
- Multiple long-term alliances with large pharmaceutical and biotechnology companies
- A $60 million clinical development collaboration with Symphony Capital Partners, L.P. for three of Lexicon's lead programs
- A $550 million investment plan
Lexicon's Five-Year Investment Plan
In June 2007, Lexicon entered into a major financing agreement with The Invus Group, LLC (“Invus”) to help fund its strategic goal of transitioning into an integrated biopharmaceutical company. Under the agreement, Invus invested $205 million in 2007. In addition, Lexicon stockholders, including Invus, may invest an additional $345 million over the next several years. These investments will provide up to approximately $550 million in operating capital to help Lexicon achieve its 10TO10 goal of advancing 10 new drug candidates into human clinical trials by the end of 2010.
 Corporate Profile
Lexicon Quick Facts
Investor Relations Contact
Bobbie Faulkner
Manager, Investor Relations
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381-1160
281.863.3000
Media Relations Contact
Steven Tragash
Executive Director, Corporate Affairs
Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands, TX 77381-1160
281.863.3000
Analyst Coverage
Ladenburg Thalmann & Co. - Sharon Seiler, Ph.D.
Morgan Stanley - Sapna Srivastava, Ph.D.
Piper Jaffray - Edward Tenthoff
RBC Capital Markets - Jason Kantor, Ph.D.
|
